TIL TIL
Company Profile ↓Company Overview
TIL (TIL) is a publicly traded company listed on with a market capitalization of $49.24M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -67.34% |
| 6 Months: | +2.40% |
| 3 Months: | -7.28% |
| 1 Month: | -6.32% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.82 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 77.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.00K | 42.00K | 52.00K | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.48M | 12.90M | 15.02M | 9.56M | 6.02M |
| Operating Income | -3.86M | -4.59M | -7.71M | -23.40M | -35.38M | -43.02M | -54.29M | -58.72M | -56.65M | -58.45M | -20.99M | -66.72M | -23.95M | -14.13M | -23.63M | - | -14.48M | -12.90M | -15.02M | -9.56M | -6.02M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.82M | -19.80M | -11.99M | -7.40M | -2.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 886.00K | 1.58M | 1.58M | 776.00K | 1.36M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.20M | -21.39M | -13.59M | -8.19M | -4.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.09M | -9.20M | -7.26M | -23.13M | -35.31M | -43.01M | -54.12M | -58.99M | -56.22M | -57.07M | -18.66M | -67.43M | -24.30M | -14.92M | -23.02M | - | -28.20M | -21.39M | -13.59M | -8.19M | -4.20M |
| Diluted EPS | -0.31 | -0.55 | -0.43 | -0.66 | -0.27 | -0.33 | -0.42 | -0.46 | -0.43 | -8.77 | -2.87 | -10.37 | -3.74 | -2.29 | -3.54 | -1.82 | -4.32 | -3.24 | -2.01 | - | -0.62 |
| R&D Expense | 2.01M | 2.24M | 4.91M | 14.42M | 21.19M | 29.06M | 39.17M | 41.50M | 39.66M | 20.67M | 8.46M | 8.49M | 7.26M | 2.92M | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 138.00K | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 203.29M | 87.16M | 56.05M | 51.96M |
| Operating Income | -33.64M | - | -203.29M | -87.16M | -56.05M | -51.96M |
| EBITDA | - | - | -217.38M | -147.12M | -62.53M | -65.80M |
| Interest Expense | - | - | 1.88M | 4.21M | 8.00M | 5.04M |
| Pretax Income | - | - | -225.25M | -156.09M | -74.14M | -71.37M |
| Tax Provision | - | 39.00K | -2.07M | 0 | - | - |
| Net Income | -37.74M | - | -223.18M | -156.09M | -74.14M | -71.37M |
| Diluted EPS | -2.36 | - | -34.40 | -24.00 | -11.39 | -10.70 |
| R&D Expense | 19.40M | 107.25M | 141.06M | 39.60M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 319.01M | - | 482.13M | 325.63M | 263.57M | 203.52M |
| Current Assets | - | - | - | 269.38M | 160.76M | 124.47M | 191.43M |
| Cash & Equivalents | - | 241.71M | - | 43.72M | 9.20M | 8.80M | 6.64M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 848.00K |
| Total Liabilities | - | 26.64M | - | 118.52M | 99.80M | 94.13M | 89.66M |
| Current Liabilities | - | 13.28M | - | 32.79M | 10.56M | 7.90M | 4.84M |
| Long Term Debt | - | - | - | 72.35M | 81.43M | 84.19M | 84.81M |
| Total Debt | - | - | - | 79.90M | 86.05M | 86.89M | 85.18M |
| Total Equity | -6.89M | -39.60M | - | 363.61M | 225.83M | 169.44M | 113.87M |
| Shares Outstanding | - | - | - | 6.50M | 6.50M | 6.53M | 6.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.62M | - | -180.16M | -82.03M | -55.70M | -36.62M |
| Investing Cash Flow | -51.12M | - | 114.54M | 41.13M | 53.97M | 25.48M |
| Financing Cash Flow | 313.05M | - | 71.89M | 8.08M | 1.75M | 7.29M |
| Capital Expenditure | -50.82M | - | -84.59M | -20.66M | -10.00M | -10.00M |
| Free Cash Flow | -80.43M | - | -264.75M | -102.69M | -65.70M | -46.62M |
| Net Change in Cash | - | - | 6.26M | -32.82M | 33.00K | -3.85M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -24,379.7% | - | - | - | - | - |
| Net Margin % | -27,346.4% | - | - | - | - | - |
| ROE % | 95.3% | - | -61.4% | -69.1% | -43.8% | -62.7% |
| ROCE % | -11.0% | - | -45.2% | -27.7% | -21.9% | -26.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TIL
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a…
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current operating plan beyond 2027 DALLAS, March 2…
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil, has decided to discontinue clinical development of AXN-2510 and that Ax…
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“’2510”) monotherapy in adult patients with advanced solid tumorsDALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stag…
TIL — Frequently Asked Questions
What is the current share price of TIL?
As of 2026-08-05 17:25 PDT, TIL trades at $7.26 on NASDAQ/NYSE. Its 52-week range is $6.66 to $31.50.
What is the market capitalisation of TIL?
TIL has a market capitalisation of $49.24M on NASDAQ/NYSE.
What is the P/E ratio of TIL?
TIL trades at a trailing price-to-earnings (P/E) ratio of -0.68. Its price-to-book (P/B) ratio is 0.43.
What is the return on equity (ROE) of TIL?
TIL has a return on equity (ROE) of -62.68%. Its return on capital employed (ROCE) is -26.15%.
Is TIL a good stock to buy?
This page provides a data-driven analysis of TIL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.